Modifiable patient factors are associated with the late decline in renal function following liver transplantation

Clinical Transplantation

Volumn 26, Issue 3, 2012, Pages

  Leithead, Joanna A ^a   Ferguson, James W ^b   Hayes, Peter C ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Chronic kidney disease; Decline; Glomerular filtration rate; Liver transplantation; Progression

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; PREDNISOLONE; TACROLIMUS;

ADULT; AGING; ARTICLE; CREATININE BLOOD LEVEL; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE; DELAYED GRAFT FUNCTION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; HYPERTENSION; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84862254287     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2012.01650.x     Document Type: Article

References (36)

1. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003: 349: 931.
2. Fried LF, Katz R, Sarnak MJ et al. Kidney function as a predictor of non cardiovascular mortality. J Am Soc Nephrol 2005: 16: 3728.
3. O'Riordan A, Wong V, Mccormick PA, Hegarty JE, Watson AJ. Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant 2006: 21: 2630.
4. NKF K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification; Guideline 1: Definition and stages of chronic kidney disease.
5. Cohen AJ, Stegall MD, Rosen CB et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002: 8: 916.
6. Distant DA, Gonwa TA. The kidney in liver transplantation. J Am Soc Nephrol 1993: 4: 129.
7. Gonwa TA, Mai ML, Melton LB et al. End-stage renal disease (ESRD) after orthoptic liver transplantation (OLTx) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001: 72: 1934.
8. Fisher NC, Nightingale PC, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998: 66: 59.
9. Moreno JM, Cuervas-Mons V, Rubio E et al. Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transpl Proc 2003: 35: 1907.
10. Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 1999: 10: 1136.
11. Ojo AO. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol 2007: 27: 498.
12. Olyaei AJ, De Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventative strategies. Curr Opin Crit Care 2001: 7: 384.
13. Yoshida EM, Marotta PJ, Greig PD et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs a standard-dose tacrolimus and mycophenolate mofetil regimen: a multi-center randomised clinical trial. Liver Transpl 2005: 11: 1064.
14. Neuberger JM, Mamelok RD, Neuhaus P et al. Delayed introduction of reduced dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' Study. Am J Transplant 2009: 9: 327.
15. Calmus Y, Kamar N, Gugenheim J et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. Transplantation 2010: 89: 1504.
16. NKF K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification; Guideline 2: Evaluation and treatment.
17. NKF K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification; Guideline 13: Factors associated with loss of kidney function in chronic kidney disease.
18. Gill JS, Tonelli M, Mix CH, Johnson N, Pereira BJG. The effect of maintenance immunosuppression medication on the change in kidney allograft function. Kidney Int 2004: 65: 692.
19. Pillebout E, Nochy D, Hill G et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005: 5: 1120.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999: 130: 461.
21. NKF K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification; Guideline 4: Estimation of GFR.
22. Gill JS, Tonelli M, Mix XH, Pereira BJG. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol 2003: 14: 1636.
23. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003: 9: 741.
24. Boudjema K, Camus C, Saliba F et al. Reduced-dose tacrolimus with mycophenolate mofetil vs standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 2011: 11: 965.
25. Pageaux G, Rostaing L, Calmus Y et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006: 12: 1755.
26. Pageaux G, Rostaing L, Calmus Y et al. Mycophenolate mofetil (MMF) in combination with low-doses of calcineurin-inhibitors (CNI) for chronic renal dysfunction after liver transplantation (LT): 2-year results of a prospective, multi-center, randomised study. Hepatology 2007: 46(suppl1): 233A.
27. Cicinnati VR, Yu Z, Klein CG et al. Clinical Trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients - assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther 2007: 26: 1195.
28. Schlitt HJ, Barkmann A, Boker KHW et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001: 357: 587.
29. Reich DJ, Clavien PA, Hodge EE, for the MMF Renal Dysfunction After Liver Transplantation Working Group. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomised prospective, multi-center pilot study results. Transplantation 2005: 80: 18.
30. Kronborg J, Solbu M, Njolstad I, Toft I, Eriksen BO, Jenssen T. Predictors of change in estimated GFR: a population-based 7-year follow-up from the Tromso study. Nephrol Dial Transplant 2008: 23: 2818.
31. Halbesma N, Brantsma AH, Bakker SJL et al. Gender differences in predictors of the decline of renal function in the general population. Kidney Int 2008: 74: 505.
32. Agarwal R. Effects of statins on renal function. Mayo Clin Proc 2007: 82: 1381.
33. Levey AS, Gassman JJ, Hall PP, Walker WG. Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. Modification of diet in renal disease (MDRD) study group. J Am Soc Nephrol 1991: 1: 1087.
34. Barnett AG, Van Der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005: 34: 215.
35. Neal DA, Tom BD, Gimson AE, Gibbs P, Alexander GJ. Hyperuricemia, gout and renal function after liver transplantation. Transplantation 2001: 72: 1689.
36. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthoptic liver transplantation: evaluation of current equations. Liver Transpl 2004: 10: 301.